Previous work in our laboratory had shown that the anti-HLA-DR4/glutamic acid decarboxylase (GAD)555–567 TCRL antibody, directed towards a peptide derived from type 1 diabetes autoantigen GAD, was able to block the T-cell response in vivo (10). Here, GAD1 is linked to type 1 diabetes mellitus.